Back

Trends in angiotensin receptor/neprilysin inhibitor (ARNI) prescribing across multi-Centre, multi-ethnic heart failure population

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (1) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Ms Chelfi Zhi Fei Chua

Sarawak Heart Center, Kuching (Malaysia)

5 More presentations in this session

Presentation thumbnail
Clinical and safety outcomes of a pharmacist-led medication therapy management clinic (MTM) for heart failure patients in a tertiary hospital in Singapore
Doctor W. Lin (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Guideline-directed medical therapy optimization among multi-ethnic groups of heart failure with reduced ejection fraction patients
Ms C. Chua (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Levosimendan in outpatients with Advanced heart failure and severe KidnEy disease: the out-LAKE registry
Doctor G. Uccello (Lecco, IT)
Abstract Slides Video
Presentation thumbnail
Trend of echocardiographic parameters, ventricular-arterial coupling, and biomarkers in advanced heart failure patients undergoing intermittent home-based levosimendan infusion
Doctor R. Pugliese (Brindisi, IT)
Abstract Slides Video
Presentation thumbnail
Intermittent levosimendan in advanced palliative heart failure improves quality of life and reduces heart failure decompensations: a single center-experience
Doctor J. Quintal (Setubal, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (1)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Guideline-directed medical therapy optimization among multi-ethnic groups of heart failure with reduced ejection fraction patients
thumbnail
Congress Presentation
Angiotensin receptor-neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure on replacement therapy
thumbnail
Congress Presentation
Angiotensin receptor-neprilysin inhibitor (Sacubitril/Valsartan) in cancer therapy-related cardiac dysfunction: real-world experience from a nurse-led cardio-oncology clinic

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources